Published in Tumour Biol on March 08, 2005
Release and activity of histone in diseases. Cell Death Dis (2014) 1.10
Predictive and prognostic value of circulating nucleosomes and serum biomarkers in patients with metastasized colorectal cancer undergoing Selective Internal Radiation Therapy. BMC Cancer (2012) 0.94
Combination of SELDI-TOF-MS and data mining provides early-stage response prediction for rectal tumors undergoing multimodal neoadjuvant therapy. Ann Surg (2007) 0.90
Circulating nucleosomes as epigenetic biomarkers in pancreatic cancer. Clin Epigenetics (2015) 0.87
Relevance of circulating nucleosomes and oncological biomarkers for predicting response to transarterial chemoembolization therapy in liver cancer patients. BMC Cancer (2011) 0.80
Early prediction of therapy response in patients with acute myeloid leukemia by nucleosomal DNA fragments. BMC Cancer (2006) 0.76
Novel Diagnostic and Predictive Biomarkers in Pancreatic Adenocarcinoma. Int J Mol Sci (2017) 0.75
Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol (2006) 4.70
Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases. Nat Med (2010) 4.32
Lipid-related markers and cardiovascular disease prediction. JAMA (2012) 3.91
Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients. Clin Cancer Res (2004) 2.81
Magnetic resonance colonography for the detection of colorectal neoplasia in asymptomatic adults. Gastroenterology (2013) 2.71
Methylation of serum DNA is an independent prognostic marker in colorectal cancer. Clin Cancer Res (2006) 2.13
Investigation of miR-21, miR-141, and miR-221 in blood circulation of patients with prostate cancer. Tumour Biol (2011) 1.85
MicroRNAs in renal cell carcinoma: diagnostic implications of serum miR-1233 levels. PLoS One (2011) 1.79
Prognostic and therapeutic significance of carbohydrate antigen 19-9 as tumor marker in patients with pancreatic cancer. Oncology (2006) 1.58
Post-treatment circulating plasma BMP6 mRNA and H3K27 methylation levels discriminate metastatic prostate cancer from localized disease. Clin Chim Acta (2010) 1.47
Assessing prognosis in metastatic pancreatic cancer by the serum tumor marker CA 19-9: pretreatment levels or kinetics during chemotherapy? Onkologie (2007) 1.42
Clinical use of circulating nucleosomes. Crit Rev Clin Lab Sci (2009) 1.41
Circulating microRNAs in serum: novel biomarkers for patients with bladder cancer? World J Urol (2012) 1.39
Tumor markers in breast cancer- European Group on Tumor Markers recommendations. Tumour Biol (2005) 1.36
Soluble MICA in malignant diseases. Int J Cancer (2006) 1.36
Antiangiogenic therapy with mammalian target of rapamycin inhibitor RAD001 (Everolimus) increases radiosensitivity in solid cancer. Clin Cancer Res (2008) 1.35
Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events. Nat Clin Pract Cardiovasc Med (2009) 1.31
Prognostic value of CA 19-9, CEA, CRP, LDH and bilirubin levels in locally advanced and metastatic pancreatic cancer: results from a multicenter, pooled analysis of patients receiving palliative chemotherapy. J Cancer Res Clin Oncol (2013) 1.29
Cell-free DNA in serum and plasma: comparison of ELISA and quantitative PCR. Clin Chem (2005) 1.27
Prognosis of patients with hepatocellular carcinoma. Validation and ranking of established staging-systems in a large western HCC-cohort. PLoS One (2012) 1.25
Plasma atrial natriuretic peptide and brain natriuretic peptide are increased in septic shock: impact of interleukin-6 and sepsis-associated left ventricular dysfunction. Intensive Care Med (2003) 1.25
Soluble NKG2D ligands: prevalence, release, and functional impact. Front Biosci (2008) 1.24
Plasma TIMP-1 and CEA in detection of primary colorectal cancer: a prospective, population based study of 4509 high-risk individuals. Scand J Gastroenterol (2010) 1.24
Importance of performance status for treatment outcome in advanced pancreatic cancer. World J Gastroenterol (2007) 1.23
Clinical relevance of circulating nucleosomes in cancer. Ann N Y Acad Sci (2008) 1.23
Nucleosomes, ProGRP, NSE, CYFRA 21-1, and CEA in monitoring first-line chemotherapy of small cell lung cancer. Clin Cancer Res (2008) 1.22
Analysis of serum microRNAs (miR-26a-2*, miR-191, miR-337-3p and miR-378) as potential biomarkers in renal cell carcinoma. Cancer Epidemiol (2012) 1.20
OPG is regulated by beta-catenin and mediates resistance to TRAIL-induced apoptosis in colon cancer. Clin Cancer Res (2008) 1.20
Nucleosomal DNA fragments in autoimmune diseases. Ann N Y Acad Sci (2006) 1.16
Methylation of NEUROG1 in serum is a sensitive marker for the detection of early colorectal cancer. Am J Gastroenterol (2011) 1.16
Afamin and apolipoprotein A-IV: novel protein markers for ovarian cancer. Cancer Epidemiol Biomarkers Prev (2009) 1.15
Simvastatin initiated early after heart transplantation: 8-year prospective experience. Circulation (2003) 1.14
Soluble MICB in malignant diseases: analysis of diagnostic significance and correlation with soluble MICA. Cancer Immunol Immunother (2006) 1.11
Magnetic resonance imaging as a supplement for the clinical staging system of Durie and Salmon? Cancer (2002) 1.08
Circulating nucleosomes predict the response to chemotherapy in patients with advanced non-small cell lung cancer. Clin Cancer Res (2004) 1.08
Evaluation of reference genes for the analysis of serum miRNA in patients with prostate cancer, bladder cancer and renal cell carcinoma. Int J Urol (2012) 1.07
Circulating microparticles in breast cancer patients: a comparative analysis with established biomarkers. Anticancer Res (2008) 1.04
Nucleosomes and CYFRA 21-1 indicate tumor response after one cycle of chemotherapy in recurrent non-small cell lung cancer. Lung Cancer (2008) 1.03
Prognostic relevance of oncological serum biomarkers in liver cancer patients undergoing transarterial chemoembolization therapy. Tumour Biol (2011) 1.03
Variability of linezolid concentrations after standard dosing in critically ill patients: a prospective observational study. Crit Care (2014) 1.02
Circulating nucleosomes and immunogenic cell death markers HMGB1, sRAGE and DNAse in patients with advanced pancreatic cancer undergoing chemotherapy. Int J Cancer (2013) 1.02
Prognostic relevance of CA 19-9, CEA, CRP, and LDH kinetics in patients treated with palliative second-line therapy for advanced pancreatic cancer. Tumour Biol (2010) 1.02
Circulating immunogenic cell death biomarkers HMGB1 and RAGE in breast cancer patients during neoadjuvant chemotherapy. Tumour Biol (2012) 1.01
Immunogenic cell death biomarkers HMGB1, RAGE, and DNAse indicate response to radioembolization therapy and prognosis in colorectal cancer patients. Int J Cancer (2013) 1.00
Oral capecitabine in gemcitabine-pretreated patients with advanced pancreatic cancer. Oncology (2008) 1.00
Chemoembolization combined with pravastatin improves survival in patients with hepatocellular carcinoma. Digestion (2008) 0.99
The diagnostic accuracy of two human epididymis protein 4 (HE4) testing systems in combination with CA125 in the differential diagnosis of ovarian masses. Clin Chem Lab Med (2011) 0.98
Measurements of complement factor H-related protein (BTA-TRAK assay) and nuclear matrix protein (NMP22 assay)--useful diagnostic tools in the diagnosis of urinary bladder cancer? Clin Chem Lab Med (2003) 0.97
Application of a time-varying covariate model to the analysis of CA 19-9 as serum biomarker in patients with advanced pancreatic cancer. Clin Cancer Res (2010) 0.96
Methylation of helicase-like transcription factor in serum of patients with colorectal cancer is an independent predictor of disease recurrence. Eur J Gastroenterol Hepatol (2009) 0.96
Prognostic role of methylated free circulating DNA in colorectal cancer. Int J Cancer (2012) 0.95
Relevance of histone marks H3K9me3 and H4K20me3 in cancer. Anticancer Res (2012) 0.94
Predictive value of CA 125 and CA 72-4 in ovarian borderline tumors. Clin Chem Lab Med (2009) 0.94
Predictive and prognostic value of circulating nucleosomes and serum biomarkers in patients with metastasized colorectal cancer undergoing Selective Internal Radiation Therapy. BMC Cancer (2012) 0.94
Alternative antibody for the detection of CA19-9 antigen: a European multicenter study for the evaluation of the analytical and clinical performance of the Access GI Monitor assay on the UniCel Dxl 800 Immunoassay System. Clin Chem Lab Med (2008) 0.93
Early and specific prediction of the therapeutic efficacy in non-small cell lung cancer patients by nucleosomal DNA and cytokeratin-19 fragments. Ann N Y Acad Sci (2006) 0.93
DNA integrity in plasma and serum of patients with malignant and benign diseases. Ann N Y Acad Sci (2008) 0.92
Circulating cell-free methylated DNA and lactate dehydrogenase release in colorectal cancer. BMC Cancer (2014) 0.92
Nucleosomes in serum of patients with early cerebral stroke. Cerebrovasc Dis (2005) 0.92